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ABSTRACT
Objective: To evaluate the impact of age-adjusted Charlson comorbidity index (ACCI) in 
predicting disease-free survival (DFS), overall survival (OS), and cancer-specific survival 
(CSS) among surgically treated patients with vulvar carcinoma. The secondary aim is to 
evaluate its impact as a predictor of the pattern of recurrence.
Methods: We retrospectively evaluated data of patients that underwent surgical treatment 
for vulvar cancer from 1998 to 2016. ACCI at the time of primary surgery was evaluated and 
patients were classified as low (ACCI 0–1), intermediate (ACCI 2–3), and high risk (>3). DFS, 
OS and CSS were analyzed using the Kaplan-Meir and the Cox proportional hazard models. 
Logistic regression model was used to assess predictors of distant and local recurrence.
Results: Seventy-eight patients were included in the study. Twelve were classified as low, 36 
as intermediate, and 30 as high risk according to their ACCI. Using multivariate analysis, 
ACCI class was an independent predictor of worse DFS (hazard ratio [HR]=3.04; 95% 
confidence interval [CI]=1.54–5.99; p<0.001), OS (HR=5.25; 95% CI=1.63–16.89; p=0.005) 
and CSS (HR=3.79; 95% CI=1.13–12.78; p=0.03). Positive nodal status (odds ratio=8.46; 
95% CI=2.13–33.58; p=0.002) was the only parameter correlated with distant recurrence at 
logistic regression.
Conclusion: ACCI could be a useful tool in predicting prognosis in surgically treated vulvar 
cancer patients. Prospective multicenter trials assessing the role of ACCI in vulvar cancer 
patients are warranted.
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INTRODUCTION
Approximately half of vulvar cancer patients are aged 70 or older at the time of diagnosis [1]. 
Women's life expectancy has been increasing worldwide [2] and, consequently, so have age 
related comorbidities. Comorbidity seems to be correlated with poor prognosis in different 
tumors [3-6]; however, only few reports for gynecological tumors exist. Age-adjusted 
Charlson comorbidity index (ACCI) seems to be a predictor of survival in endometrial cancer 
[7] and ovarian cancer [8].
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To our knowledge only one study has evaluated the effect of the Charlson comorbidity index 
(CCI) on overall survival (OS) in vulvar cancer patients [9]. No one study has evaluated the 
impact of the age-adjusted comorbidity index on survival (OS, disease-free survival [DFS] and 
cancer-specific survival [CSS]) in vulvar cancer patients.
Due to the scarcity of data examining the prognostic impact of medical comorbidity on 
survival for vulvar cancer, the primary aim of this study is to evaluate the impact of the 
age-adjusted Charlson comorbidity score in predicting DFS, OS, and CSS among surgically 
treated patients with vulvar carcinoma. The secondary aim of the study is to evaluate the 
impact of ACCI as a predictor of the pattern of recurrence.
MATERIALS AND METHODS
For the present study, our internal database was analyzed from 1998 to 2016. Following 
IRB approval (CDD034/2015 of 23/11/2015), we retrospectively reviewed our prospectively 
maintained database searching for patients that have undergone surgical treatment for 
vulvar cancer.
Inclusion criteria were histologically confirmed squamous carcinoma or adenocarcinoma 
of the vulva. Exclusion criteria were recurrent disease, pre-invasive lesions (VIN 1–3), or 
uncommon histology (melanoma, Paget's disease, basalioma).
Demographic data, operative and pathological reports, and clinical outcomes were extracted 
from the database. Missing data and data concerning pre-existing medical conditions present 
at the time of primary surgery were extracted from the patient's medical records. Patients 
whose medical records had insufficient data concerning their medical history were also 
excluded from the analysis.
ACCI was calculated by summing the weighted comorbidities and age of each patient. A 
binomial value (present or absent) was assigned to 19 different comorbidities. If present the 
following parameters were assigned 1 point: myocardial infarction, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease (cerebrovascular accident [CVA] with mild 
or no residua) or transient ischemic attack [TIA], dementia, chronic obstructive pulmonary 
disease, connective tissue disease, peptic ulcer disease, mild liver disease, and diabetes without 
end organ damage. If present the following parameters were assigned 2 points: hemiplegia, 
moderate or severe renal disease, diabetes with end organ damage, solid tumor without 
metastases (exclude if >5 years from diagnosis), leukemia and lymphoma. If present the 
following parameters were assigned 3 points: moderate or severe liver disease. If present the 
following parameters were assigned 6 points: metastatic solid tumor and acquired immune 
deficiency syndrome (not just human immunodeficiency virus positive). Moreover, for each 
life decade after 40 years of age, a point was added until a maximum of 4 points (1 point for age 
50–59, 2 points for age 60–69, 3 points for age 70–79, and 4 points for age ≥80).
Vulvar cancer was not considered in the score assessment (6 points for solid tumor), and any 
new medical conditions that developed after the date of surgical treatment were omitted. 
The overall score corresponds to the weighed sum of 19 medical conditions and patient age 
[10]. Patients were classified into 3 groups based on their ACCI score (ACCI 0–1= low;  
ACCI 2–3 = intermediate; ACCI >3 = high).
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Standard statistical analysis was used to evaluate descriptive analysis such as mean, 
frequencies and percentages. Incidence of event was analyzed for statistical significance by 
using the Fisher exact test. Normality testing (D'Agostino and Pearson test) was performed to 
determine whether data were sampled from a Gaussian distribution. The t-test and Mann-
Whitney U test were used to compare continuous parametric and non-parametric values, 
respectively.
Predicting variables were evaluated for their association with distant and local recurrences on 
the basis of logistic regression model. Odds ratio (OR) and 95% confidence intervals (CIs) 
were calculated for each comparison.
DFS was calculated in months from the date of surgery to the last follow-up or date of first 
recurrence, OS was calculated in months from the date of surgery to the last follow-up or date 
of death, and CSS was calculated in months from the date of surgery to the last follow-up or 
date of death from disease.
Five-year DFS, OS, and CSS were estimated using the Kaplan-Meier curve. Cox regression 
analysis was used to calculate both univariate and multivariate analysis for variables 
influencing DFS, OS, and CSS. Multivariable models were performed for variables with a p 
value 0.10 based on univariate analysis. Associations were summarized by calculating hazard 
ratio (HR) and corresponding 95% CI. All calculated p values were 2-sided. The p value 
<0.05 were considered statistically significant. Statistical analysis was performed with IBM 
Microsoft's SPSS Statistics version 24.0 for Mac (IBM Corp., Armonk, NY, USA).
RESULTS
Seventy-eight patients met the inclusion criteria of this study. In Table 1 are reported the 
patients surgical and pathological characteristics. Mean age was 67.9±10.3 and mean BMI was 
27.5±5.5. The most represented histology was squamous cell carcinoma (96.2%). Thirty-four 
patients (43.6%) were diagnosed at early stage (stage IA–IB), 27 (34.6%) at stages II and III, 
and 6 (7.7%) had advanced disease (stage IV). Twelve patients were classified as ACCI low risk 
0–1 (15.4%), 36 as intermediate risk (46.2%), and 30 as high risk (38.5%).
Considering factors influencing DFS, we observed using univariate analysis that age >75 
(HR=1.93; 95% CI=1.06–3.53; p=0.033), positive nodes >2 (HR=3.03; 95% CI=1.48–6.22; 
p=0.003), stage (HR=1.40; 95% CI=1.04–1.79; p=0.026), and ACCI (HR=1.80; 95% CI=1.19–
2.72; p=0.005) were correlated with 5-year DFS (Table 2). Considering factors influencing 
DFS we observed using multivariate analysis that more than 2 positive nodes (HR=8.94; 95% 
CI=2.67–29.97; p<0.001) and ACCI (HR=3.04; 95% CI=1.54–5.99; p<0.001) were independent 
predictors (Table 2).
Five-year DFS was 45.8% for all patients. Negative nodal status had a 50.5% 5-year DFS, 
whereas it was 24.3% in positive node status (p=0.007). Five-year DFS was 80.8%, 46.9% and 
28% for low ACCI, intermediate ACCI and high ACCI (p=0.009), respectively. Fig. 1 shows 
DFS according ACCI class.
Considering factors influencing CSS we observed using univariate analysis that age >75 
(HR=3.69; 95% CI=1.61–8.47; p=0.002), positive nodes >2 (HR=3.02; 95% CI=1.11–8.20; 
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p=0.03), stage (HR=1.25; 95% CI=0.27–5.75; p=0.08), and ACCI (HR=3.59; 95% CI=1.7–5.56; 
p=0.001) were correlated with 5-year CSS (Table 2). Considering factors influencing CSS 
we observed using multivariate analysis that more than 2 positive nodes (HR=5.25; 95% 
CI=1.45–19.05; p=0.012) and ACCI (HR=3.79; 95% CI=1.13–12.78; p=0.031) were independent 
predictors (Table 2). Fig. 2 shows CSS according ACCI class.
Considering factors influencing OS we observed that at univariate analysis that age >75 
(HR=2.78; 95% CI=1.24–6.26; p=0.013), positive nodes >2 (HR=3.40; 95% CI=1.33–8.67; 
p=0.01), stage (HR=1.28; 95% CI=0.35–4.71; p=0.07), and ACCI (HR=3.93; 95% CI=1.86–8.31; 
p<0.001) were correlated with 5-year OS (Table 2). Considering factors influencing OS we 
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Table 1. Surgical and pathological characteristics
Variables Values
Age at diagnosis 67.9±10.3
BMI 27.5±5.5
Histology
Squamous 75 (96.2)
Adenocarcinoma 3 (3.8)
Grade
1 16 (20.5)
2 33 (42.3)
3 15 (19.2)
Missing 14 (17.9)
FIGO stage
IA 11 (14.1)
IB 23 (29.5)
II 13 (16.7)
III 14 (17.9)
IV 6 (7.7)
Missing 11 (14.1)
Symptoms at diagnosis
Bleeding 8 (10.3)
Pruritus 36 (46.2)
Mass 10 (12.8)
ACCI score
Low risk (0–1) 12 (15.4)
Intermediate risk (2–3) 36 (46.2)
High risk (>3) 30 (38.5)
Surgical procedure
Skin vulvectomy 3 (3.8)
Local excision 11 (14.1)
Hemivulvectomy 29 (37.2)
Radical vulvectomy 35 (44.9)
Flap 21 (26.9)
Monolateral lymphadenectomy 18 (23.1)
Bilateral lymphadenectomy 47 (60.3)
Tumor size (mm) 29.4±17.9
Tumor-free resection margins
>10 mm 48 (61.5)
>5 mm 12 (15.4)
5 mm 11 (14.1)
Infiltrated 7 (9)
Number of removed lymph nodes 16.6±11.9
Node positive patients 19 (24.4)
Number of positive nodes* 3.3±3.4
Values are presented as number of patients (%) or mean±standard deviation.
ACCI, age-adjusted Charlson comorbidity index; BMI, body mass index; FIGO, International Federation of 
Gynecology and Obstetrics.
*Among positive-node patients.
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observed that at multivariate analysis more than 2 positive nodes (HR=7.72; 95% CI=2.05–28.98; 
p=0.002) and ACCI (HR=5.25; 95% CI=1.63–16.89; p=0.005) were independent predictors 
(Table 2). Fig. 3 shows OS and according ACCI class.
Among 49 patients that recurred, 32 (65.3%) were local, and 17 (34.7%) were distant. 
Considering factors influencing local recurrence, there was a non-statistical association 
with close margins at logistic regression (OR=2.89; 95% CI=0.87–9.54; p=0.08). The 
presence of 2 or more positive nodes independently correlated with the occurrences of 
distant recurrence (OR=8.46; 95% CI=2.13–33.58; p=0.002). There was a non-significant 
statistical association between obesity, adenocarcinoma histology and occurrence of 
distant recurrence.
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Fig. 2. Kaplan-Meier curve of CSS according to ACCI class. 
ACCI, age-adjusted Charlson comorbidity index; CSS, cancer-specific survival.
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Fig. 1. Kaplan-Meier curve of DFS according to ACCI class. 
ACCI, age-adjusted Charlson comorbidity index; DFS, disease-free survival.
DISCUSSION
Vulvar cancer is one of the least common gynecological cancers, and the role of its prognostic 
factors is far from clear [11,12]. The major finding of the present study is the correlation 
between ACCI and OS, CSS, and DFS.
The impact of ACCI on DFS is possibly associated with the increased probability of receiving 
suboptimal treatment in patients with multiple comorbidities making them at increased 
risk for disease recurrence and mortality. These findings seem to be in accordance with the 
literature [13-18].
A recent analysis of a SEER database has clearly demonstrated the importance of surgery 
in vulvar cancer treatment [19]. This study showed that patients who underwent surgical 
procedure had a better prognosis (HR=0.4; 95% CI=0.24–0.69; p<0.001). In our study, 
the patients analyzed had all been treated with curative intent, and presumably extensive 
demolition surgery had been avoided in patients with high comorbidities because of the 
inherent risk of increased complication. In support of this, we found that the presence of 
close margins (<5 mm) are more frequently found among patients with intermediate (35%) or 
high risk (38%) ACCI was compared to low risk (14%), although it should be noted that this 
difference is not statistically significant. Furthermore, some studies report that complication 
rates seem to be increased in patients with multiple comorbidities [20-22] and often their 
management delays the access to adjuvant treatment [23,24], if required. We also found 
that the ACCI was correlated with longer postoperative stay in patients submitted to more 
extensive surgical procedure. In our study patients submitted to radical vulvectomy with high 
ACCI score had a significant (p=0.007) longer postoperative stay (13.73±14.4) compared to 
those with intermediate/low ACCI score (9±4.80).
ACCI is an independent predictor of OS. Our study is the first to correlate the ACCI with OS in 
vulvar cancer. This finding is in line with a recent study that found that the CCI was correlated 
with increased risk of death [9]. According to the literature [19] age is considered an 
7/10https://ejgo.org https://doi.org/10.3802/jgo.2019.30.e6
Age-adjusted Charlson comorbidity index, vulvar
0 20 60
O
S
0.4
0.2
1.0
12040 80 100
Intermediate risk (2–3)
Low risk (0–1)
High risk (>3)
Time (mo)
0.8
0.6
Fig. 3. Kaplan-Meir curve of OS according to ACCI class. 
ACCI, age-adjusted Charlson comorbidity index; OS, overall survival.
independent predictor of OS. However, in our study although age was a predictor of survival 
using univariate analysis, it was not confirmed using multivariate analysis, suggesting 
that, more than age itself, rather age-related comorbidity independently correlates with 
mortality rate. An even more interesting finding is the association between ACCI and CSS. 
This could be associated with a more aggressive behavior of the tumor affecting elderly 
patients with multiple comorbidities, this finding seems to be in line with the literature 
[25-27]. This suggests that treatment should not only focus on the cancer itself [28-30] but 
also on the various comorbidities that affect survival. The major limitation of this study is 
its retrospective nature and the number of patients included that limits the possibility to 
have firm conclusions. However, because vulvar cancer is a rare disease, it is very difficult to 
conduct large prospective evaluation of prognostic factors of this neoplasm. In the present 
study, presumably, more aggressive treatment had been avoided in patients with high 
comorbidities because of the inherent risk of increased complications. For that reason, even 
if tested using multivariate analysis, age could represent a confounding factor. Prospective 
multicenter trials assessing ACCI to validate our findings are therefore warranted.
In conclusion, to our knowledge our study is the first to evaluate the impact of the age 
adjusted comorbidity index on survival in vulvar cancer patients. ACCI evaluation could be a 
useful tool in predicting prognosis in surgically treated vulvar cancer patients. During initial 
patient assessment, ACCI could prove useful in assessing risk of mortality from cancer and 
could ultimately be used as a tool for a more tailored, individualized patient management.
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